ReviewNature reviews. Rheumatology2018
The B cell response to citrullinated antigens in the development of rheumatoid arthritis.
Review in Nature reviews. Rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05502731 (Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis), which is not on this map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis
Who cites it
55 citing papers in PubMed, 110 citations in OpenAlex.
- CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.Nature medicine · 2026Trial
- Neutrophil Extracellular Trap Formation-Derived Peptidylarginine Deiminases in the Citrullination of Oral Bacteria to Promote Inflammation in Rheumatoid Arthritis.The Journal of rheumatology · 2026Article
- Cross-presentation of citrullinated antigens drives cytotoxic CD8bioRxiv : the preprint server for biology · 2026Article
- Citrullination in tumor immunity and therapy.The Journal of clinical investigation · 2025Review
- Impact of interaction between IL-21 gene variants and smoking status on susceptibility to rheumatoid arthritis.BMC medical genomics · 2025Article
- Pathogenic Role of Cytokines in Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- Advances in plant-derived vesicle like nanoparticles-based therapies for inflammatory diseases.Asian journal of pharmaceutical sciences · 2025Review
- Time sequence of autoimmune processes in the trajectory to rheumatoid arthritis development: what do we know?RMD open · 2025Review
- Citrullinated Autoantigen-Specific T and B Lymphocytes in Rheumatoid Arthritis: Focus on Follicular T Helper Cells and Expansion by Coculture.ACR open rheumatology · 2025Article
- A small-scale preliminary study utilizing mass cytometry to distinguish two forms of arthritis.Clinical rheumatology · 2025Article
- Fcγ-receptor-IIIA bioactivity of circulating and synovial immune complexes in rheumatoid arthritis.RMD open · 2024Article
- Identification of common mechanisms and biomarkers for dermatomyositis and atherosclerosis based on bioinformatics analysis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Pathogenesis of autoimmune disease.Nature reviews. Nephrology · 2023Review
- An Integrated Glycosylation Signature of Rheumatoid Arthritis.Biomolecules · 2023Article
- IL-21 (rs2055979 and rs2221903)/Genes · 2023Article
- Article
- Rheumatoid arthritis sera antibodies to citrullinated collagen type II bind to joint cartilage.Arthritis research & therapy · 2022Article
- Multicellular immune dynamics implicate PIM1 as a potential therapeutic target for uveitis.Nature communications · 2022Article
- Benchmarking computational methods for B-cell receptor reconstruction from single-cell RNA-seq data.NAR genomics and bioinformatics · 2022Article
- Mechanism-driven strategies for prevention of rheumatoid arthritis.Rheumatology & autoimmunity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune response to citrullinated antigens is found almost exclusively in patients with rheumatoid arthritis (RA). It is a dynamic response that expands before the onset of disease and generates antibodies (anti-citrullinated protein antibodies (ACPAs)) that are extensively glycosylated in the variable domain. This feature of ACPAs is remarkable and warrants detailed investigation, as it can offer insights into the earliest immunologic mechanisms that lead up to the development of RA. The acquisition of variable domain glycans, in fact, could enable ACPA-expressing B cells to breach tolerance. Although the underlying mechanisms are still elusive, data to support this concept are emerging, owing to the reliable identification and isolation of citrullinated antigen-directed B cells from patients with RA. This technological proficiency also allows for the generation of an increasing number of well-defined monoclonal ACPAs, and provides the opportunity to test and define the mechanisms by which the citrullinated antigen-directed B cell response contributes to the onset and persistence of inflammation. Together with a revised perception of the HLA-risk effect and novel insights into how T cells can govern antibody effector functions, these developments shape an increasingly clear picture of the B cell response to citrullinated antigens in the development of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.